Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

Department of Medicine, Lund University, Sweden.

OBJECTIVES: Inhibitors of the glucagon-like peptide-1 (GLP-1)-degrading enzyme, dipeptidyl peptidase IV (DPPIV), are being explored in the treatment of diabetes. We examined the long-term influence of a selective, orally active inhibitor of DPPIV (NVP DPP728), in normal female C57BL/6J mice and such mice rendered glucose-intolerant and insulin-resistant by feeding a high-fat diet. DESIGN: In mice fed a standard diet (11% fat) or a high-fat diet (58% fat), NVP DPP728 (0.12 micromol/g body weight) was administered in the drinking water for an 8 week period. RESULTS: DPPIV inhibition reduced plasma DPPIV activity to 0.01+/-0.03 mU/ml vs 3.26+/-0.19 mU/ml in controls (P<0.001). Glucose tolerance after gastric glucose gavage, as judged by the area under the curve for plasma glucose levels over the 120 min study period, was increased after 8 weeks by NVP DPP728 in mice fed normal diet (P=0.029) and in mice fed a high-fat diet (P=0.036). This was accompanied by increased plasma levels of insulin and intact GLP-1. Glucose-stimulated insulin secretion from islets isolated from NVP DPP728-treated animals after 8 weeks of treatment was increased as compared with islets from control animals at 5.6, 8.3 and 11.1 mmol/l glucose both in mice fed normal diet and in mice fed a high-fat diet (both P<0.05). Islet insulin and glucagon immunocytochemistry revealed that NVP DPP728 did not affect the islet architecture. However, the expression of immunoreactive glucose transporter isoform-2 (GLUT-2) was increased by DPPIV inhibition, and in mice fed a high-fat diet, islet size was reduced after treatment with NVP DPP728 from 16.7+/-2.6 x 10(3) microm(2) in controls to 7.6+/-1.0 x 10(3) microm(2) (P=0.0019). CONCLUSION: Long-term DPPIV inhibition improves glucose tolerance in both normal and glucose-intolerant mice through improved islet function as judged by increased GLUT-2 expression, increased insulin secretion and protection from increased islet size in insulin resistance.

This article has been cited by other articles:

				H. Duez, A. C. Smith, C. Xiao, A. Giacca, L. Szeto, D. J. Drucker, and G. F. Lewis Acute Dipeptidyl Peptidase-4 Inhibition Rapidly Enhances Insulin-Mediated Suppression of Endogenous Glucose Production in Mice Endocrinology, January 1, 2009; 150(1): 56 - 62. [Abstract] [Full Text] [PDF]

				S. Huttner, E. U. Graefe-Mody, B. Withopf, A. Ring, and K. A. Dugi Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers J. Clin. Pharmacol., October 1, 2008; 48(10): 1171 - 1178. [Abstract] [Full Text] [PDF]

				M. Salehi, B. A. Aulinger, and D. A. D'Alessio Targeting {beta}-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins Endocr. Rev., May 1, 2008; 29(3): 367 - 379. [Abstract] [Full Text] [PDF]

				A. C. C. Girardi, L. E. Fukuda, L. V. Rossoni, G. Malnic, and N. A. Reboucas Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule Am J Physiol Renal Physiol, February 1, 2008; 294(2): F414 - F422. [Abstract] [Full Text] [PDF]

				O. B. Chaudhri, K. Wynne, and S. R. Bloom Can Gut Hormones Control Appetite and Prevent Obesity? Diabetes Care, February 1, 2008; 31(Supplement_2): S284 - S289. [Abstract] [Full Text] [PDF]

				H. Chahal and T.A. Chowdhury Gliptins: a new class of oral hypoglycaemic agent QJM, November 1, 2007; 100(11): 671 - 677. [Abstract] [Full Text] [PDF]

				D. J. Drucker Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes: Preclinical biology and mechanisms of action Diabetes Care, June 1, 2007; 30(6): 1335 - 1343. [Full Text] [PDF]

				R. Mussmann, M. Geese, F. Harder, S. Kegel, U. Andag, A. Lomow, U. Burk, D. Onichtchouk, C. Dohrmann, and M. Austen Inhibition of GSK3 Promotes Replication and Survival of Pancreatic Beta Cells J. Biol. Chem., April 20, 2007; 282(16): 12030 - 12037. [Abstract] [Full Text] [PDF]

				K. Yamazaki, N. Yasuda, T. Inoue, E. Yamamoto, Y. Sugaya, T. Nagakura, M. Shinoda, R. Clark, T. Saeki, and I. Tanaka Effects of the Combination of a Dipeptidyl Peptidase IV Inhibitor and an Insulin Secretagogue on Glucose and Insulin Levels in Mice and Rats J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 738 - 746. [Abstract] [Full Text] [PDF]

				R K. Campbell Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus Ann. Pharmacother., January 1, 2007; 41(1): 51 - 60. [Abstract] [Full Text] [PDF]

				P. Aschner, M. S. Kipnes, J. K. Lunceford, M. Sanchez, C. Mickel, D. E. Williams-Herman, and for the Sitagliptin Study 021 Group Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes Diabetes Care, December 1, 2006; 29(12): 2632 - 2637. [Abstract] [Full Text] [PDF]

				K. Yamazaki, N. Yasuda, T. Inoue, T. Nagakura, K. Kira, M. Shinoda, T. Saeki, and I. Tanaka 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one Is a Novel Competitive and Selective Inhibitor of Dipeptidyl Peptidase IV with an Antihyperglycemic Activity J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1253 - 1257. [Abstract] [Full Text] [PDF]

				G. A. Herman, A. Bergman, C. Stevens, P. Kotey, B. Yi, P. Zhao, B. Dietrich, G. Golor, A. Schrodter, B. Keymeulen, et al. Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4612 - 4619. [Abstract] [Full Text] [PDF]

				M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]

				B. F. Burkey, X. Li, L. Bolognese, B. Balkan, M. Mone, M. Russell, T. E. Hughes, and P. R. Wang Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant Rats J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 688 - 695. [Abstract] [Full Text] [PDF]

				B. Ahren, G. Pacini, J. E. Foley, and A. Schweizer Improved Meal-Related {beta}-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1Year Diabetes Care, August 1, 2005; 28(8): 1936 - 1940. [Abstract] [Full Text] [PDF]

				B. Ahren and T. E. Hughes Inhibition of Dipeptidyl Peptidase-4 Augments Insulin Secretion in Response to Exogenously Administered Glucagon-Like Peptide-1, Glucose-Dependent Insulinotropic Polypeptide, Pituitary Adenylate Cyclase-Activating Polypeptide, and Gastrin-Releasing Peptide in Mice Endocrinology, April 1, 2005; 146(4): 2055 - 2059. [Abstract] [Full Text] [PDF]

				S. Xu, B. Zhu, Y. Teffera, D. E. Pan, C. G. Caldwell, G. Doss, R. A. Stearns, D. C. Evans, and M. G. Beconi METABOLIC ACTIVATION OF FLUOROPYRROLIDINE DIPEPTIDYL PEPTIDASE-IV INHIBITORS BY RAT LIVER MICROSOMES Drug Metab. Dispos., January 1, 2005; 33(1): 121 - 130. [Abstract] [Full Text] [PDF]

				M. S. Winzell and B. Ahren The High-Fat Diet-Fed Mouse: A Model for Studying Mechanisms and Treatment of Impaired Glucose Tolerance and Type 2 Diabetes Diabetes, December 1, 2004; 53(suppl_3): S215 - S219. [Abstract] [Full Text] [PDF]

				C. F. Deacon Therapeutic Strategies Based on Glucagon-Like Peptide 1 Diabetes, September 1, 2004; 53(9): 2181 - 2189. [Abstract] [Full Text] [PDF]

				N. Yasuda, T. Inoue, T. Nagakura, K. Yamazaki, K. Kira, T. Saeki, and I. Tanaka Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa Rats J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 614 - 619. [Abstract] [Full Text] [PDF]

				C M. B Edwards GLP-1: target for a new class of antidiabetic agents? J R Soc Med, June 1, 2004; 97(6): 270 - 274. [Full Text] [PDF]

				D. A. D'Alessio and T. P. Vahl Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890. [Abstract] [Full Text] [PDF]

				B. Ahren, M. Landin-Olsson, P.-A. Jansson, M. Svensson, D. Holmes, and A. Schweizer Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2078 - 2084. [Abstract] [Full Text] [PDF]

				L. Zhu, C. Tamvakopoulos, D. Xie, J. Dragovic, X. Shen, J. E. Fenyk-Melody, K. Schmidt, A. Bagchi, P. R. Griffin, N. A. Thornberry, et al. The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides: IN VIVO METABOLISM OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE-(1-38) J. Biol. Chem., June 13, 2003; 278(25): 22418 - 22423. [Abstract] [Full Text] [PDF]

				J. A. Pospisilik, J. Martin, T. Doty, J. A. Ehses, N. Pamir, F. C. Lynn, S. Piteau, H.-U. Demuth, C. H.S. McIntosh, and R. A. Pederson Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates {beta}-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats Diabetes, March 1, 2003; 52(3): 741 - 750. [Abstract] [Full Text] [PDF]